Spapen H, Van Berlaer G, Moens M, Hubloue I
Department of l'Intensive Care, University Hospital, Vrije Universiteit Brussels, Belgium.
Acta Clin Belg. 2011 Jan-Feb;66(1):42-5. doi: 10.2143/ACB.66.1.2062512.
In experimental bacterial meningitis, adjunctive steroid treatment reduces the inflammatory response in the cerebrospinal fluid and subarachnoidal space, thereby improving neurological outcome. The clinical application of this concept was sustained by the European Dexamethasone Study which showed a beneficial effect of dexamethasone on neurological outcome and mortality in adult patients with bacterial--in particular S. pneumoniae-- meningitis. A thorough analysis of the data of this landmark trial as well as results from more recent trials in children and adults with bacterial meningitis worldwide do not support the use of adjunctive dexamethasone in meningitis. Moreover, dexamethasone may have detrimental effects with regard to antibiotic efficacy and late severe neurological complications. Until further data about steroid use in bacterial meningitis becomes available, we propose that dexamethasone therapy in this setting should be abandoned.
在实验性细菌性脑膜炎中,辅助使用类固醇治疗可减轻脑脊液和蛛网膜下腔的炎症反应,从而改善神经功能预后。欧洲地塞米松研究证实了这一概念在临床中的应用价值,该研究表明地塞米松对成年细菌性脑膜炎患者(尤其是肺炎链球菌性脑膜炎患者)的神经功能预后和死亡率具有有益影响。对这一具有里程碑意义的试验数据以及全球范围内针对儿童和成人细菌性脑膜炎的最新试验结果进行全面分析后发现,不支持在脑膜炎中使用辅助性地塞米松。此外,地塞米松可能对抗生素疗效和晚期严重神经并发症产生不利影响。在获得关于细菌性脑膜炎中使用类固醇的更多数据之前,我们建议应放弃在这种情况下使用地塞米松治疗。